Evofem Biosciences (EVFM) Misses Q3 EPS by 34c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Evofem Biosciences (EVFM) Reports Complete Phase 3 Clinical Trial of Amphora for Prevention of Pregnancy
November 8, 2018 6:51 AM ESTEvofem Biosciences, Inc., (NASDAQ: EVFM) today announced the last patient has completed her last visit in AMPOWER, the second Phase 3 clinical trial of Amphora® (L-lactic acid, citric acid and potassium bitartrate), its lead Multipurpose Vaginal pH Regulator (MVP-R) product candidate, for the prevention of pregnancy.
Amphora is an investigational, first-in-class MVP-R designed to give a woman control over some of the most intimate issues of her life and health. This non-hormonal, non-systemic vaginal gel is being developed for woman-controlled birth control as well as prevention of certain sexually transmitted infections... More
